Byrne C.J

Nov 14, 2023 | cell.com | Byrum S.D |Byrne C.J |Sun Yat-sen

Highlights•The tumor suppressor p53 transcriptionally induces CMBL expression•CMBL promotes TRIM25-induced ubiquitination and degradation of PFKP•CMBL inhibits glycolysis and the growth of CRC cells•p53-inducing agents and 2-DG coordinately suppress CMBL-deficient CRCSummaryAerobic glycolysis is critical for cancer progression and can be exploited in cancer therapy.

Oct 31, 2023 | cell.com | Byrne C.J |Lauren Podmore |Catherine Iorio |Kevin Nixon

Highlights•Insulin receptor (INSR) is broadly expressed in breast cancer (BC)•INSR deletion suppresses mammary tumorigenesis driven by Her2 and PyMT oncogenes•INSR affects tumor initiation, not progression and metastasis•INSR upholds bioenergetic fitness of mammary epithelial cellsSummaryBreast cancer (BC) prognosis and outcome are adversely affected by obesity. Hyperinsulinemia, common in the obese state, is associated with higher risk of death and recurrence in BC.

Oct 17, 2023 | cell.com | Byrne C.J |Sarah Carden |Elisa Vitiello

Highlights•CAPture enables affinity purification of mammalian centrosomes•CAPture utilizes a peptide derived from CCDC61 to isolate centrosomes•Combined with mass spectrometry CAPture delivers high-coverage proteomes•CAPture will facilitate centrosome research in health and diseaseSummaryCentrosomes are the major microtubule-organizing centers in animals and play fundamental roles in many cellular processes.

Sep 25, 2023 | cell.com | Byrne C.J |Sun Yat-sen

Highlights•Lysosomal cyst(e)ine storage and release maintains GSH levels for ROS buffering•MFSD12 is phosphorylated by mTORC1 at T254 to control lysosomal cyst(e)ine storage•MFSD12-T254A mutant acts as a dominant-negative inhibitor of MFSD12 functions•MFSD12 upregulation induces chemoresistance and poor prognosis in breast cancerSummaryCyst(e)ine is a key precursor for the synthesis of glutathione (GSH), which protects cancer cells from oxidative stress.

Aug 15, 2023 | cell.com | Byrne C.J

Highlights•BF10 demonstrates efficacy against macrophage-enriched tumors•BF10 depletes tumor-associated macrophages•BF10 enhances cytotoxicity and metabolic reprogramming of CD8+ T cells•The combination of BF10 and αPD-1 further enhances antitumor activitySummaryStrategies to increase intratumoral concentrations of an anticancer agent are desirable to optimize its therapeutic potential when said agent is efficacious primarily within a tumor but also have significant systemic side effects.